Article
Improvement of cardiac function by placenta-derived mesenchymal stem cells does not require permanent engraftment and is independent of the insulin signaling pathway.
Stem cell research & therapy - 21 Aug 2014
Passipieri Juliana A, Kasai-Brunswick Tais H, Suhett Grazielle, Martins Andreza B, Brasil Guilherme V, Campos Dilza B, Rocha Nazareth N, Ramos Isalira P, Mello Debora B, Rodrigues Deivid C, Christie Beatriz B, Silva-Mendes Bernardo J, Balduíno Alex, Sá Renato M, Lopes Laudelino M, Goldenberg Regina C, Campos de Carvalho Antonio C, Carvalho Adriana B
Abstract excerpt
INTRODUCTION: The objective of this work was to evaluate the efficacy of placenta-derived mesenchymal stem cell (MSC) therapy in a mouse model of myocardial infarction (MI). Since MSCs can be obtained from two different regions of the human term placenta (chorionic plate or villi), cells obtained from both these regions were compared so that the best candidate for cell therapy could be selected. METHODS: For the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
